IAS

IAS
July 23-26, 2023
Brisbane, Australia

International AIDS Society .

Explore more information for Gilead HIV / AIDS therapies
Results (11)

LENACAPAVIR ORAL BRIDGING (300 MG QW) MAINTAINS EFFICACY WITH A SIMILAR SAFETY PROFILE WHEN SC LEN CANNOT BE ADMINISTERED

RECOMMENDATIONS FOR MISSED ORAL LENACAPAVIR LOADING DOSES USING POPULATION-PHARMACOKINETICS- BASED SIMULATIONS

PHARMACOKINETIC BRIDGING WITH ORAL LENACAPAVIR FOR MISSED SUBCUTANEOUS Q6M DOSING

PATIENT-REPORTED OUTCOMES FROM THE CAPELLA CLINICAL TRIAL OF HEAVILY TREATMENT-EXPERIENCED ADULTS LIVING WITH HIV

WEIGHT CHANGE AND METABOLIC ASSESSMENT OF VIROLOGICALLY SUPPRESSED CHILDREN WITH HIV AGED ≥2 YEARS AND WEIGHING 14 TO <25 KG WHO RECEIVED A TAF-CONTAINING REGIMEN

LONGITUDINAL LYMPHOCYTE DYNAMICS IN VIROLOGICALLY SUPPRESSED CHILDREN WITH HIV INITIATING SINGLE-TABLET E/C/F/TAF

COMPARISON OF LONG-ACTING LENACAPAVIR PHASE 2/3 REGIMEN VS SIMPLIFIED REGIMEN USING POPULATION-PK ANALYSIS AND SIMULATION

WEEK 96 RESULTS OF ALLIANCE, A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING B/F/TAF VERSUS DTG+F/TDF IN TREATMENT-NAÏVE HIV- 1/HEPATITIS B (HBV) COINFECTION

PHARMACOKINETICS, SAFETY, AND EFFICACY OF B/F/TAF IN VIROLOGICALLY SUPPRESSED PREGNANT WOMEN WITH HIV

PREEXISTING AND POSTBASELINE RESISTANCE ANALYSES IN POOLED PEDIATRIC STUDIES OF EMTRICITABINE/TENOFOVIR ALAFENAMIDE (F/TAF)-BASED ANTIRETROVIRAL THERAPY (ART)

HEALTHCARE PROVIDER EXPERIENCE OF ADMINISTERING LONG-ACTING LENACAPAVIR FOR PEOPLE WITH HIV WITH HEAVY TREATMENT EXPERIENCE ENGAGED THROUGH A COMPASSIONATE USE PROGRAM IN THE UNITED STATES